Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells by 源�踰뺤슦 et al.
www.neoplasia.com
Volume 20 Number 2 February 2018 pp. 197–206 197
Abbreviati
transition;
Address all
Hospital,
Eonjuro,
Ki Cheon
Medicine,
Email: ggi
1Funding:
Program oAnti-cancer Effects of HNHA and
Lenvatinib by the Suppression of
EMT-Mediated Drug Resistance in
Cancer Stem Cells1,2ons: ATC, anaplastic thyroid cancer; EMT, epithelial-mesenchymal
PTC, papillary thyroid cancer; TKI, tyrosine kinase inhibitors.
correspondence to: Hang-Seok Chang, M.D., Ph.D., Gangnam Severance
Department of Surgery, Yonsei University College of Medicine, 211
Gangnam-gu, Seoul 135-720, Korea. E-mail: SURGHSC@yuhs.ac or
g Park., Ph. D., Department of Surgery, Yonsei University College of
50-1, Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of Korea.
ru95@yuhs.ac
This research was supported by he "SEBANG" Faculty Research Assistance
f Yonsei University College of Medicine 6-2013-0160 and the Basic ScienceYong Sang Lee*,†, 3, Seok-Mo Kim*,†, 3,
Bup-Woo Kim*,†, Ho Jin Chang*,†, Soo Young
Kim*,†, Cheong Soo Park*,†, Ki Cheong Park*,‡, 3
and Hang-Seok Chang*,†, 3
*Thyroid Cancer Center, Gangnam Severance Hospital,
Department of Surgery, Yonsei University College of
Medicine, Seoul 120-752, Korea; †Gangnam Severance
Hospital, Department of Surgery Yonsei University College
of Medicine 211 Eonjuro, Gangnam-gu, Seoul 135-720,
Korea; ‡Department of Surgery, Yonsei University College of
Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul, 120-752
KoreaAbstract
Anaplastic thyroid cancer (ATC) constitutes less than 2% of total thyroid cancers but accounts for 20–40% of
thyroid cancer-related deaths. Cancer stem cell drug resistance represents a primary factor hindering treatment.
This study aimed to develop targeted agents against thyroid malignancy, focusing on individual and synergistic
effects of HNHA (histone deacetylase), lenvatinib (FGFR), and sorafenib (tyrosine kinase) inhibitors. Patients with
biochemically and histologically proven papillary thyroid cancer (PTC) and ATC were included. Cell samples were
obtained from patients at the Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of
Medicine, Seoul, Korea. PTC and ATC cells were treated with lenvatinib or sorafenib, alone or in combination with
HNHA. Tumor-bearing mice (10/group) were administered 10 mg/kg lenvatinib (p.o.) or 40 mg/kg sorafenib (p.o.),
alone or in combination with 25 mg/kg HNHA (i.p.) once every three days. Gene expression in patient-derived PTC
and ATC cells was compared using a microarray approach. Cellular apoptosis and proliferation were examined by
immunohistochemistry and MTT assays. Tumor volume and cell properties were examined in the mouse xenograft
model. HNHA-lenvatinib combined treatment induced markers of cell cycle arrest and apoptosis and suppressed
anti-apoptosis markers, epithelial-mesenchymal transition (EMT), and the FGFR signaling pathway. Combined
treatment induced significant tumor shrinkage in the xenograft model. HNHA-lenvatinib combination treatment
thus blocked the FGFR signaling pathway, which is important for EMT. Treatment with HNHA-lenvatinib
combination was more effective than either agent alone or sorafenib-HNHA combination. These findings have
implications for ATC treatment by preventing drug resistance in cancer stem cells.
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Thyroid cancer represents more than 90% of all endocrine cancer cases,
and its incidence has increased over the past three decades [1,2].
Thyroid cancer encompasses a broad scope of tumors derived from
follicular cells that range from well-differentiated papillary (PTC) and
follicular cancer (FTC), which generally have a favorable prognosis,
through anaplastic thyroid cancer, a clinically aggressive form with poor
prognosis, including poorly differentiated (PDTC) and undifferentiated
thyroid cancer [3–5]. In particular, the advanced cancer subtype (ATC)
has a poor prognosis owing to its resistance to treatment and aggressive
behavior [5,6]. The total median survival is only a few months [6,7].
Poorly differentiated cancers are often resistant to anti-cancer
drugs; moreover, effective clinical guidelines for ATC are currently
lacking [7]. However, recent evidence has shown that induction of
the epithelial-mesenchymal transition (EMT) in cancer cells not only
results in metastasis, but also serves as a major contributing factor in
drug resistance [8,9]. Nevertheless, the mechanisms of EMT-
mediated drug resistance remain unclear. EMT is a physiological
process in which epithelial cells exhibit collapse of cell–cell junctions
and temporary or permanent transition to a condition that is
characteristic of migratory cells [10]. Although EMT constitutes a
fundamental aspect of resistance to ErbB-targeting compounds, a lack
of knowledge regarding the molecular mechanisms underlying this
process has prevented progress in the development of therapeutic
approaches targeting this drug-resistant state [11,12]. Previous
research has shown that fibroblast growth factor receptor 1
(FGFR1) expression is significantly induced during TGF-β-
mediated EMT and plays a crucial role in metastatic cancer
[13–15]. These previous studies suggest that the drug resistance of
poorly differentiated cancer stem cells (CSCs) is related to EMT,
which is mediated by the FGFR signaling pathway [16,17]. Although
various molecules and mechanisms are closely associated with poor
clinical outcomes for advanced thyroid cancer [18,19], we focused on
EMT and drug resistance in CSCs to explain these poor clinical
results [8,20]. In particular, in this study we examined the
mechanisms underlying drug resistance, including FGFR signaling
and EMT, in response to current treatments and methods to address
the issues associated with resistance.
Materials and Methods
Patients and Tissue Specimens
Fresh tumors were obtained from patients with biochemical and
histologically proven PTC and ATC who were treated at the Thyroid
Cancer Center, Gangnam Severance Hospital, Yonsei University
College of Medicine, Seoul, Korea. Fresh tumors were acquired during
surgical resection of thyroid cancer primary and metastatic sites. Several
patients with thyroid cancer were chosen depending on cancer subtype.
The research protocol was approved by the Institutional Review Board
of the Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei
University College of Medicine (IRB Protocol: 3–2016-0076).
Tumor Cell Isolation and Primary Culture
After resection, tumors were kept in normal saline with antifungal
and antibiotics and moved to the laboratory. Normal tissue and fat
were removed and the tissues were rinsed with 1× Hank's Balanced
Salt Solution. Tumors were minced in a tube with dissociation
medium containing DMEM/F12 with 20% fetal bovine serum
supplemented with 1 mg/ml collagenase type IV (Sigma, St. Louis,MO; C5138). Minced and suspended tumor cells were filtered
through sterile nylon cell strainers with 70-micron pores (BD Falcon,
Franklin Lakes, NJ, USA), rinsed with 50 ml of 1× Hank's Balanced
Salt Solution, and centrifuged at 220 g for 5 minutes. Cells were
resuspended in RPMI-1640 (Hyclone, South Logan, UT) medium
with 10% fetal bovine serum (Hyclone) and 2% penicillin/
streptomycin solution (Gibco, Grand Island, NY, USA). Cell
viability was determined using the trypan blue dye exclusion method.
Cell Culture
The patient-derived PTC, ATC and resistance to sorafenib ATC
cells were isolated and grown in RPMI-1640 medium with 10% fetal
bovine serum (cells were authenticated by short tandem repeat
profiling, karyotyping, and isoenzyme analysis).
Cell Viability Assay
Cell proliferation was measured using the MTT assay. Cells were
seeded in 96-well plates at 6 × 103 cells per well and incubated
overnight to achieve 80% confluency. The indicated drugs were
added to achieve final concentrations of 0–100 μM. Cells were
incubated for the indicated times prior to the determination of cell
viability using the MTT reagent according to the manufacturer's
protocol (Roche, Basel, Switzerland; 11,465,007,001). Absorbance
was measured at 550 nm. Viable cells were counted by trypan blue
exclusion. Data were expressed as a percentage of the signal observed
in vehicle-treated cells and are shown as the means ± SEM of triplicate
experiments.
Microarray Experiment and Data Analysis
RNA purity and integrity were evaluated using an ND-1000
Spectrophotometer (NanoDrop, Wilmington, DE) and an Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). RNA
labeling and hybridization were performed by using the Agilent
One-Color Microarray-Based Gene Expression Analysis protocol
(Agilent Technology, V 6.5, 2010). Briefly, 100 ng of total RNA
from each sample was linearly amplified and labeled with Cy3-dCTP.
The labeled cRNAs were purified using an RNAeasy Mini Kit
(Qiagen, Venlo, The Netherlands). The concentration and specific
activity of the labeled cRNAs (pmol Cy3/μg cRNA) were measured
using the NanoDrop ND-1000. Then, 600 ng of each labeled cRNA
was fragmented by adding 5 μl 10× blocking agent and 1 μl of 25×
fragmentation buffer, and then heated at 60 °C for 30 minutes.
Finally, 25 μl of 2× GE hybridization buffer was added to dilute the
labeled cRNA. Hybridization solution (40 μl) was dispensed into the
gasket slide and assembled to the Agilent SurePrint G3 Human GE
8X60K, V3 Microarrays (Agilent®). Raw data were extracted using
Agilent Feature Extraction Software (v11.0.1.1). The raw data for
each gene were then summarized automatically in an Agilent feature
extraction protocol to generate the raw data text file, providing
expression data for each gene probed on the array. Gene-enrichment
and functional annotation analysis for the significant probe list was
performed using gene ontology (www.geneontology.org/) and Kyoto
Encyclopedia for Genes and Genomes (KEGG) (http://kegg.jp)
analyses. All data analysis and visualization of differentially expressed
genes were conducted using R 3.1.2 (www.r-project.org).
Immunofluorescence Analysis and Confocal Imaging
The expression of β-catenin was analyzed by immunofluorescence
staining. Cells grown on glass-bottomed dishes (MatTek, Ashland,
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Abingdon, UK) for 10 minutes and permeabilized with 0.5%
TritonX-100 in phosphate buffered saline (PBS) for 10 minutes.
Slides were air-dried, washed with PBS, and incubated with
anti-β-catenin (1:25; Abcam, Cambridge, UK) in 3% bovine serum
albumin in PBS. After being washed with PBS, slides were incubated
with Alexa 488 (1:200; Molecular Probes, Eugene, OR) Nuclei were
stained with Hoechst 33,342 (Life Technologies, Grand Island, NY)
for visualization. Images were observed under a confocal microscope
(LSM Meta 700; Zeiss, Oberkochen, Germany) and were analyzed
using Zeiss LSM Image Browser, version 4.2.0121.
Immunoblot Analysis
Cells were washed twice with cold PBS and lysed on ice with protein
extraction buffer (Pro-Prep, iNtRON Biotechnology, Seoul, Korea)
following the manufacturer's protocol. Protein concentrations were
determined by a BCA assay (Pierce Biotechnology, Rockford, IL).
Equal amounts of protein (20 μg) were separated on 8–10% sodium
dodecyl sulfate-polyacrylamide gels; the resolved proteins were
electro-transferred onto polyvinylidene fluoride membranes (Millipore,
Bedford, MA). The membranes were subsequently blocked with 5%
nonfat milk in TBS-T for 1 hour at room temperature and incubated
with appropriate concentrations of primary antibodies against Ki-67,
Vimentin, E-cadherin, Apaf-1, Snail, Zeb1 (all from Abcam), Cyclin
D1, CDK4, p21, p53, p-ERK 1/2, ERK 1/2, p-NFκB, Bcl-2, Caspase
3, and β-actin (all from Santa Cruz Biotechnology, Dallas, TX)
overnight at 4 °C. The membranes were then rinsed 3–5 times with
TBST and probed with the corresponding secondary antibodies
conjugated to horse radish peroxidase (Santa Cruz) at room temperature
for 1 hour. After rinsing, blots were developed with ECL reagents
(Pierce) and exposed usingKodakX-OMATARFilm (EastmanKodak,
Rochester, NY) for 3–5 minutes.
Flow Cytometry Analysis of the Cell Cycle
Cells were treated with sorafenib and lenvatinib alone or in
combination in RPMI-1640 medium containing 10% fetal bovine
serum for 40 hours, harvested by trypsinization, and fixed with 70%
ethanol. Cells were stained for total DNA using PBS containing 40
μg/ml propidium iodide and 100 μg/ml RNase I for 30 minutes at 37
°C. The cell cycle distribution was then analyzed using the
FACSCalibur Flow Cytometer (BD Biosciences, San Jose, CA).
The proportions of cells in the sub-G0/G1, G0/G1, S, and G2/M
phases were analyzed using FlowJo v8 for MacOSX (Tree Star,
Ashland, OR). This experiment was repeated in triplicate and the
results were averaged.
Human Thyroid Cancer Cell Xenografts
The patient-derived PTC and ATC cells (3.5 × 106 cells/mouse)
were cultured in vitro and then injected subcutaneously into the
upper left flank region of female BALB/c nude mice. After 11 days,
tumor-bearing mice were assigned to groups randomly (n = 10/
group) and administered 10 mg/kg lenvatinib (p.o.) and 40 mg/kg
sorafenib (p.o.), either alone or in combination with 25 mg/kg
HNHA (given i.p.) once every 2 days. Tumor size was measured
every three day using calipers. Tumor volume was estimated using
the following formula: L × S2/2 (L, longest diameter; S, shortest
diameter). Animals were maintained under specific pathogen-free
conditions. All experiments were approved by the Animal Experiment
Committee of Yonsei University.Immunohistochemistry
All tissues were fixed in 10% neutral-buffered formalin and
embedded in paraffin wax following standard protocols. Tissue
sections (5 μm) were dewaxed, and antigen retrieval was performed in
citrate buffer (pH 6), using an electric pressure cooker set at 120 °C
for 5 minutes. Sections were incubated for 5 minutes in 3% hydrogen
peroxide to quench endogenous tissue peroxidase. All tissue sections
were counterstained with hematoxylin, dehydrated, and mounted.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism
(GraphPad Software Inc., La Jolla, CA). Immunohistochemistry
results were evaluated by ANOVA followed by Bonferroni post-hoc
tests. Values are expressed as the means ± SD. P b .05 indicated
statistical significance.
Results
FGFR Signaling Pathway and EMT Marker Expression are
Higher in PDTC than in DTC
Given that gene expression is largely dependent on the cancer
subtype, we considered that CSCs achieve a stem-like phenotype by
transcriptional reprogramming. We performed a gene expression
microarray analysis to compare PDTC (GSA1 and GSA2) and DTC
(GSP1 and GSM1) patient-derived thyroid cancer cells (Figure 1A).
Many genes were significantly differentially expressed between PDTC
and DTC cells, suggesting that multiple biological processes were
reprogrammed depending on cancer cell differentiation. Genes
related to FGFR and EMT were particularly induced in PDTC
(Figure 1A). Consequently, we focused on the mechanism by which
drug resistance is acquired via the FGFR signaling pathway and EMT.
Patient-derived GSA1/2, GSP1, and GSM1 cells were used to analyze
the expression of genes related to human diseases (Figure 1B).
Expression patterns in patient-derived thyroid cancer cells were not
significantly different from those of other thyroid cancers, including
endometrial cancer. Together, these data show that genes related to
the FGFR signaling pathway and EMT are expressed more highly in
PDTC than in DTC.
Synergistic Effects of HNHA and Lenvatinib on Cancer Cell
Proliferation in Patient-Derived Thyroid Cancer Cells
To investigate the synergistic anticancer effects of sorafenib or
lenvatinib with HNHA on patient-derived PTC and ATC, we
assayed GSP1, GSA1, and GSA2 (Table 1, Information for PTC and
ATC from Gangnam Severance Hospital) cell proliferation in the
presence and absence of these compounds by MTT assays (Figure 2A,
C, and E). IC50 was lowest for the combination of HNHA and
lenvatinib among all treatment groups for GSP1, GSA1, and GSA2
(Table 2). Further characterization of the synergistic effect of HNHA
and lenvatinib on GSP1, GSA1, and GSA2 cell viability showed that
the combination reduced the viability of PTC and ATC cells to a
greater extent than the reduction observed for either agent alone or
the combination of HNHA and sorafenib. The combination of
HNHA and lenvatinib suppressed cell proliferation more effectively
than either agent used singly or the combination of HNHA and
sorafenib (Figure 2A, C, and E); moreover, this effect was
concentration-dependent (Figure 2B, D, and F). Collectively, these
results imply that the synergistic effect of HNHA and lenvatinib is
more potent that the effects of either agent alone or the combination
of HNHA and sorafenib in patient-derived PTC and ATC.
Figure 1. Gene expression profiles of patient-derived thyroid cancer cells. Gene expression analysis using a microarray approach in DTC
and PDTC. (A) Gene expression profiles based on microarrays. (B) KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway,
expression patterns of genes related to human disease. Hierarchical clustering analysis for the comparison of DTC and PDTC.
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and Cell Cycle Arrest in Patient-Derived Thyroid Cancer Cells
Combined treatment with HNHA and lenvatinib showed the most
significant induction of the sub-G0G1 population, resulting in the
induction of cell death in GSP1, GSA1, and GSA2 cells (Figure 2G–I).
The synergistic effect of HNHA and lenvatinibmost potently induced the
sub-G0G1 population, leading to apoptosis, cell cycle arrest, and strong
inhibition of GSP1, GSA1, and GSA2 cell viability. Immunoblot analyses
of protein levels in GSP1, GSA1, and GSA2 cell lines indicated that the
HNHAand lenvatinib combination induced themostmarked increases in
the levels of p53 and p21, which are well-known arrestors of the cell cycle,
and decreases in the levels of cyclin D1 and CDK 4, which are positive
regulators of the cell cycle, as comparedwith responses to either agent alone
or the combination of HNHA and sorafenib (Figure 2J–L). Of note, the
proliferation marker (Ki-67) and anti-apoptotic (phosphorylated NF-κB,Table 1. Cell Line Characteristics, Viability after Drug Treatment of All Thyroid Cancer Cell Lines
GSP1 G
Age at Diagnosis 31 7
Gender Female F
Primary Disease Site Thyroid T
Stage IVc I
Primary Pathology Papillary thyroid cancer A
Classification of specimen used for culture Fresh tumor F
Obtained from Gangnam Severance Hospital, Seoul, Korea Gp65, and Bcl-2) markers were most highly suppressed in the HNHA and
lenvatinib combination treatment group compared with groups treated
with either agent alone or the combination of HNHA and sorafenib
(Figure 2J–L). The expression of apoptotic markers (Apaf-1 and
cleaved-caspase 3) weremost highly induced in theHNHA and lenvatinib
combination treatment group compared with groups treated with either
agent alone or the combination of HNHA and sorafenib (Figure 2J–L).
Together, these data indicate that theHNHA and lenvatinib combination
effectively suppresses PDTC as well as DTC.
Drug Resistance of Cancer Stem Cells was Related to EMT
Induction Mediated by FGFR Signaling Pathway Activation
in GSP1, GSA1, and GSA2
We investigated whether the treatments inhibited EMT activation
by the prevention of FGFR signal transduction. The FGFR signalingExamined
SA1 GSA2
4 56
emale Male
hyroid Thyroid
Vc IVc
naplastic thyroid cancer Anaplastic thyroid cancer, resistance to Sorafenib
resh tumor Fresh tumor
angnam Severance Hospital, Seoul, Korea Gangnam Severance Hospital, Seoul, Korea
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various biological processes, including drug resistance. The combi-
nation of HNHA and lenvatinib had the greatest suppressive effects
on the FGFR signaling pathway (PKC, MEK, and p-ERK1/2), and
led to the inhibition of EMT (vimentin, snail, and zeb1) and
dramatic increases in E-cadherin compared to either agent alone or
the combination of HNHA and sorafenib in GSP1, GSA1, and
GSA2 (Figure 2M–O). With respect to ligand binding, FGFR*
63
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*
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*
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
A) B
C) D
E) F
Figure 2. Synergistic anti-cancer effect of HNHA and lenvatinib on pat
agent alone or HNHA and sorafenib in combination. Cell viability and
alone, or HNHA and sorafenib combined in patient-derived thyroid can
indicate mean % of the value observed in the solvent-treated contro
means ± SD. *P b .05 vs. control, **P b .01 vs. control, ***P b .005
and lenvatinib (G, H and I). Cells were exposed to the indicated inhibito
flow cytometry and FlowJo v8. Immunoblot analysis about markers of
proliferation, cell cycle, anti-apoptosis activity, FGFR signaling pathwa
GSA1, (K and N); GSA2, (L and O)). GSP1, GSA1 and GSA2 were expos
expression of Ki-67 (cell proliferation), Cyclin D1 and CDK4 (cell cyc
(apoptosis), p-NFκB and Bcl-2 (anti-apoptosis), PKC, MEK and phosp
Zeb1 (EMT), E-cadherin (loss of E-cadherin function promotes EMT)induced a cascade of downstream signaling pathways including
mitogen-activated protein kinase enzymes MEK and ERK (in the
MAPK pathway) and PKC, via PLCγ activation (Figure 2M–O).
These results suggest that more advanced cancer cells, CSCs, were
more resistant to drugs through EMT induction mediated by FGFR
signaling pathway activation. Synergistic effects of the HNHA and
lenvatinib combination effectively suppressed EMT induction via the
inhibition of the FGFR signaling pathway in GSP1, GSA1, and GSA2.)
)
)
ient-derived thyroid cancer cells compared with the effects of each
proliferation assay of HNHA and lenvatinib combined, each agent
cer cells (GSP1, (A and B); GSA1, (C and D); GSA2, (E and F)). Points
l. All experiments were repeated at least 3 times. Data represent
vs. control. Cell cycle arrest induced by the combination of HNHA
rs, harvested, and stained with propidium iodide before analysis by
cell cycle arrest, apoptosis, E-cadherin (negatively related to EMT),
y and EMT in patient-derived thyroid cancer cells (GSP1, (J and M);
ed to the indicated inhibitors for 24 hours prior to the analysis of the
le), p21 and p53 (cell cycle arrest), Apaf-1 and cleaved-caspase 3
horylated ERK1/2 (FGFR signaling pathway), Vimentin, Snail, and
by immunoblotting.
Status Sub-G0G1 G0G1 S G2/M
Control 2.4  0.01 35.9  0.03 34.8  0.02 26.9  0.02
Sorafenib only 18.4  0.03 43.4  0.04 22.6  0.05 15.6  0.02
Lenvatinib only 25.2  0.02 45.5  0.01 19.4  0.02 9.9  0.05
HNHA 33.4  0.04 48.7  0.01 11.4  0.05 6.5  0.05
HNHA+Sorafenib 61.4  0.01 27.8  0.06 6.8  0.03 4.0  0.03
HNHA+Lenvatinib 69.4  0.02 23.7  0.01 4.6  0.01 2.3  0.04
Status Sub-G0G1 G0G1 S G2/M
Control 1.3  0.02 45.5  0.01 30.2  0.03 23.0  0.03
Sorafenib only 14.2  0.01 46.3  0.02 20.0  0.02 19.5  0.03
Lenvatinib only 19.5  0.04 49.5  0.02 15.8  0.05 15.2  0.06
HNHA 26.8  0.05 46.7  0.02 15.9  0.05 10.6  0.01
HNHA+Sorafenib 51.8  0.05 31.5  0.04 11.5  0.02 5.2  0.06
HNHA+Lenvatinib 67.2  0.05 21.3  0.05 8.2  0.04 3.3  0.02
Status Sub-G0G1 G0G1 S G2/M
Control 0.7  0.05 41.2  0.02 41.9  0.02 16.2  0.04
Sorafenib only 4.5  0.02 40.8  0.01 39.7  0.03 15.0  0.01
Lenvatinib only 15.9  0.02 48.4  0.05 26.2  0.03 9.5  0.01
HNHA 23.4  0.01 51.3  0.03 20.5  0.01 4.8  0.04
HNHA+Sorafenib 45.7  0.02 35.4  0.01 14.8  0.05 4.1  0.02
HNHA+Lenvatinib 59.3  0.02 30.7  0.03 7.9  0.02 2.1  0.01
GSP1
GSA1
GSA2
G)
I)
H)
J)
*63 *6$ *6$
K) L)
M) N) O)
Figure 2. (continued).
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Figure 3. Lenvatinib prevents EMT through repression of β-catenin nuclear translocation in GSA1 and GSA2 cancer stem-like cells.
Immunofluorescence cytochemical staining showed that β-catenin nuclear localization was greater in GSA1 (B) and GSA2 (C) cancer
stem-like cells, than in GSP1 (A). However, these cells were sensitive to EMT inhibition via β-catenin nuclear localization by lenvatinib.
Table 2. IC50 (half maximal inhibitory concentration) Determination Using a Cell Proliferation Assay. HNHA and Lenvatinib Combination Treatment is a Lower IC50 than HNHA and Sorafenib
Combination or Sorafenib, Lenvatinib and HNHA Alone. Each Data point Represents the Mean of 3 Independent MTT Assays for IC50 Performed in Triplicate. SD, standard deviation
Cell Line Hisopathology Animal Cell Proliferation IC50*) (μM)
Sorafenib Lenvatinib HNHA HNHA ± S HNHA ± L
GSP1 Thyroid cancer: Papillary Human 9.42 (± 0.2) 10.51 (± 0.1) 5.15 (± 0.4) 4.95 (± 0.5) 3.84 (± 0.3) *
GSA1 Thyroid cancer: Anaplastic Human 23.51 (± 0.2) 41.54 (± 0.5) 20.05 (± 0.4) 9.63 (± 0.1) 6.49 (± 0.2) *
GSA2 Thyroid cancer: Anaplastic Human 21.11 (± 0.3) 35.13 (± 0.2) 18.33 (± 0.3) 11.47 (± 0.5) 7.32 (± 0.5) *
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Figure 4. Combination of HNHA and lenvatinib produced synergistic anti-cancer effects in patient-derived thyroid cancer cell xenografts in
vivo. Athymic nude mice with established tumors were treated with the indicated inhibitors. Data represent the mean tumor volumes.
Inhibition of tumor progression by combination therapy of the HNHA and lenvatinib in mice with patient-derived thyroid cancer cell (GSP1,
A–C; GSA1, D–F; and GSA2, G–I) xenografts (n = 10 mice/group). Change of tumor volume (A, D, and G). The compounds had no
significant effect on mouse body weight (B, E, and H). Weight of dissected tumors (C, F, and I). Immunohistochemical analysis of Bcl-2
protein levels in paraffin-embedded tumor tissues from mice with GSP1, GSA1, and GSA2 xenografts (J, K, and L). Synergistic activity of
the HNHA and lenvatinib combination induced more potent inhibition of tumor Bcl-2 expression than each agent used alone or HNHA and
sorafenib in combination. MetaMorph 4.6 image-analysis software was used to quantify Bcl-2 immunostaining. *P b .05; **P b .01;
***P b .005 for the comparison with the control.
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Induction by Nuclear Localization on Advanced Thyroid
Cancer Cells
β-Catenin constitutes a well-known, conserved regulatory factor
with a crucial role in a tumorigenesis that is correlated with a poor
prognosis. β-Catenin nuclear localization acts synergistically to
promote the expression of target genes related to drug resistance.
PDTC CSCs acquired drug resistance via EMT activation mediated
by β-catenin nuclear localization. In GSA1 and 2, patient-derived
anaplastic thyroid cancer 1 and 2, β-catenin nuclear localization was
greater than that in patient-derived papillary thyroid cancer 1, GSP1
(Figure 3A–C, each control panel). β-Catenin nuclear localization in
GSA1 and 2 was significantly inhibited by the FGFR inhibitor
lenvatinib as opposed to non-FGFR inhibitors, HNHA or sorafenib
(Figure 3A–C). These results indicate that the disruption of EMT
activation via FGFR signaling pathway inhibition contributed to the
efficacy against drug resistance by lenvatinib.
Significant Tumor Shrinkage was Induced by the Combination
of HNHA and Lenvatinib in a Xenograft Model
To investigate the synergistic anti-cancer effect of the combination
of HNHA and lenvatinib in vivo, we developed a mouse xenograft
tumor model using patient-derived papillary thyroid cancer cells,
GSP1, GSA1, and GSA2. Each agent used alone and the combination
of HNHA and sorafenib did not markedly suppress GSP1, GSA1,
and GSA2 cell xenograft tumors; however, the combination of
HNHA and lenvatinib resulted in tumor suppression (Figure 4A, D,
and G). Moreover, there was no evidence for systemic toxicity ortreatment-related death in any group. Mouse body weight was not
significantly influenced by treatment with sorafenib, lenvatinib, or
HNHA (Figure 4B, E, and H). The HNHA and lenvatinib
combination treatment group had significantly smaller tumor
volumes than those of mice treated with each agent used alone or
the combination of HNHA and sorafenib (Figure 4C, F, and I). As
anti-apoptotic activity is a fundamental factor in the evaluation of
tumorigenesis and Bcl-2 serves as an important marker of
anti-apoptotic activity, we identified this marker by immunohisto-
chemistry analysis of GSP1, GSA1, and GSA2 cell xenograft tumors.
This demonstrated that the HNHA and lenvatinib combination
treatment group showed the strongest decrease in Bcl-2 expression
among all groups (Figure 4J–L). Accordingly, the HNHA and
lenvatinib combination treatment was considered to have potent
anti-cancer effects in CSCs of PDTC as well as in the DTC xenograft
model.
Discussion
EMT is linked to cancer growth, including metastasis, therapeutic
resistance, and recurrence. CSCs, which are found in poorly
differentiated tumors and have stem cell-like features [21], have the
capacity for self-renewal and are associated with metastases and
therapeutic resistance [22]. Recent studies have demonstrated a link
between EMT, drug resistance, and CSCs [23]. In particular, CSCs
and EMT-type cells, which share some molecular characteristics with
CSCs, are believed to perform crucial roles in drug resistance and
cancer metastasis, as observed in some malignant cancers in humans
[23]. EMT is associated with the gain of stem cell-like properties and
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stem cell properties. Furthermore, CSCs frequently also exhibit EMT
properties. Numerous studies have examined the relationship
between EMT and drug resistance in CSCs. In the present study,
we investigated EMT-mediated drug resistance via the FGFR
signaling pathway in patient-derived anaplastic thyroid cancer cells,
a type of cancer stem-like cells. These cells exhibited high expression
of markers of the EMT and FGFR signaling pathway. Some studies
have shown that FGF2 and β3 integrin are part of an EMT signature
that contributes to FGFR1-mediated drug resistance and metastatic
progression [15]. Drug resistance of CSCs was dependent on the
EMT-associated FGFR signaling pathway. Consequently, we focused
on the effect of inhibition of the FGFR signaling pathway by tyrosine
kinase inhibitors (TKIs) on CSCs.
TKIs are suggested in patients with radioiodine-refractory DTC
with metastatic, rapidly progressive, symptomatic, and/or imminently
threatening disease that is not otherwise amenable to local control
with other approaches. Systemic therapeutics resulted in improved
progression-free survival in three randomized, double-blinded,
placebo-controlled clinical trials, i.e., vandetanib, sorafenib, and
lenvatinib [24–26]. Sorafenib inhibits RAF-1, a member of the RAF/
MEK/ERK signaling pathway, BRAF activity, and VEGFR-2,
VEGFR-3, PDGFR-β, and c-KIT [27]. Lenvatinib has a potent
inhibitory effect on VEGFR-2, VEGFR-3, PDGFRα/β, KIT, and
RET, as well as, unlike sorafenib, FGFR 1–4. The most important
difference between lenvatinib and other drugs is the ability to inhibit
FGFR 1, establishing it as an effective drug in cases in which
resistance to VEGFR inhibitors develops [28–30]. Although both
lenvatinib and sorafenib show good results in phase III trials and are
the first-line treatment in radioiodine-refractory DTCs, most patients
eventually stop responding to these agents, and many are not able to
continue medication owing to their toxicity. In patients who exhibit
disease progression during initial kinase inhibitor therapy, without
prohibitive adverse effects, only lenvatinib may be used as a
second-line treatment [24]. Several mechanisms explain TKI
resistance, such as receptor autophosphorylation, autophagy,
hypoxia-inducing factor, epigenetic regulation, and EMT [31,32].
There are several EMT-inducing cytokines, e.g., TGF-β, FGF, HGF,
insulin-like growth factor, and IL-6 [33,34]. EMT in thyroid cancer
is induced in more aggressive forms, with increased expression of
ZEB1, which can promote drug resistance via EMT-dependent and
EMT-independent mechanisms [35–37]. Studies have shown that
the down-regulation of ZEB1 expression could restore drug
sensitivity [38,39]. For example, sorafenib inhibits EMT in
hepatocellular carcinoma, attenuates HGF secretion in polarized
macrophages, and decreases plasma HGF. Sorafenib also abolishes
polarized-macrophage-induced activation of the HGF receptor Met
[40]. Notably, reversion of EMT overcomes drug resistance in lung
adenocarcinoma [33].
The present study demonstrated that the drug resistance of
CSC-like cancer cells, i.e., sorafenib-resistant-patient derived thyroid
cancer cells, was inhibited by combination therapy with HNHA and
lenvatinib through the inhibition of the EMT-mediated FGFR
signaling pathway. Synergistic effects of HNHA and lenvatinib were
more efficient than the effects of either agent used singly or the
combination of HNHA and sorafenib. The combined treatment
effectively induced markers of cell cycle arrest and apoptosis and
reduced anti-apoptosis markers, EMT, and the FGFR signaling
pathway. In addition to cell culture studies, in vivo studies using axenograft model indicated significant tumor shrinkage in the HNHA
and lenvatinib combined treatment group. We propose that these
effects might be explained by reduced EMT-mediated drug resistance
in CSCs. Specifically, the combination of HNHA and lenvatinib
blocked the FGFR signaling pathway, which is important for EMT
and metastasis [41]. Notably, these findings indicate that the
combination of HNHA and lenvatinib is a potentially effective new
clinical approach for the care of patients with CSCs with drug-
resistant properties.
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